FDA approves Contego Medical's Neuroguard IEP Direct system for carotid artery revascularisation
Contego Medical has secured FDA premarket approval for its Neuroguard IEP Direct carotid revascularisation system alongside separate clearance for its embolic protection technology, advancing an integrated approach to stroke-risk reduction during carotid artery procedures.
Contego Medical announced on 10 November 2026 that the US Food and Drug Administration had granted premarket approval for its Neuroguard IEP Direct system and separate 510(k) clearance for the Neuroguard IEP Embolic Protection System, supporting transcarotid artery revascularisation in selected patients with carotid artery stenosis.
The technology combines flow reversal with an integrated embolic protection filter, while the supporting PERFORMANCE III study reported no strokes through 30 days among the studied patients; the underlying FDA premarket approval supplement decision was dated 4 November 2026, and the observed zero-stroke result should not be interpreted as a guarantee of procedural safety.
Field | Content |
Article Type | Approvals |
Company | Contego Medical |
Primary Device | Neuroguard IEP Direct |
Additional Device | Neuroguard IEP Embolic Protection System |
Announcement Date | 10 November 2026 |
Underlying FDA Decision Date | 4 November 2026 |
Regulatory Authority | US Food and Drug Administration |
Primary Device Regulatory Pathway | Premarket approval supplement |
Primary Device Regulatory Decision | FDA approval |
Additional Device Regulatory Pathway | 510(k) |
Additional Device Regulatory Decision | FDA clearance |
Regulatory Market | United States |
Device Category | Carotid artery revascularisation and embolic protection |
Procedure | Transcarotid artery revascularisation |
Procedure Abbreviation | TCAR |
Target Patient Population | Selected patients with carotid artery stenosis |
Clinical Condition | Carotid artery stenosis |
Therapeutic Area | Vascular medicine and stroke prevention |
Technology Component One | Flow reversal |
Technology Component Two | Integrated embolic protection filter |
Technology Objective | Reduce cerebral embolisation risk during carotid revascularisation |
Supporting Clinical Study | PERFORMANCE III |
Reported Stroke Outcome | No strokes through 30 days in the studied population |
Reported 30-Day Stroke Rate | 0% in the reported study population |
Study Population Size | Not specified in supplied summary |
Long-Term Stroke Outcomes | Not specified in supplied summary |
Regulatory Distinction | FDA premarket approval and 510(k) clearance are different regulatory pathways |
Pharmaceutical Approval Involved | No |
What Happened | Contego Medical announced FDA approval for Neuroguard IEP Direct and separate clearance for an embolic protection system. |
Why It Matters | The regulatory decisions support additional device options for carotid artery procedures where preventing cerebral embolisation is a major clinical objective. |
Clinical Significance | The supporting study reported no strokes through 30 days, although this finding does not eliminate procedural risk. |
Regulatory Significance | Establishes distinct FDA approval and clearance milestones for related carotid intervention technologies. |
Timing Clarification | The FDA approval supplement decision was dated 4 November, while the company announced the milestones on 10 November 2026. |
Safety Clarification | The observed 0% stroke rate is a study result rather than a guarantee for future patients. |
Key Takeaway | Neuroguard IEP Direct received FDA approval, accompanied by separate clearance for Contego's embolic protection technology. |
What to Watch | Clinical adoption, procedural outcomes, real-world stroke rates, longer-term safety and commercial availability. |
Submitted Source | NeuroNews International |
Submitted Source URL | https://neuronewsinternational.com/us-fda-approves-contego-medicals-neuroguard-iep-direct-system-for-tcar-integrated-embolic-protection/ |
Recommended Source | Contego Medical announcement |
Recommended Source URL | https://www.prweb.com/releases/contego-medical-receives-fda-approval-for-neuroguard-iep-direct-system-for-tcar-iep-302934443.html |
Relevant Date | 10 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comentarios